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Abstract
Background: Colorectal cancer (CRC) is one of the most common malignances worldwide. Metastasis is
responsible for the rapid recurrence and poor prognosis of CRC. However, the underlying molecular mechanism of
CRC metastasis remains largely unclear. In this study we purposed to investigate the expression and biological
functions of miR-490-3p in CRC metastasis, as well as to identify its downstream target genes and influenced
pathway.
Methods: The expression level of miR-490-3p in CRC cell lines, CRC adjacent normal tissues, non-metastasis and
metastasis tissues were assessed by quantitative real-time PCR. Patient survivals were follow-up up to 7 years. Gain-
of-function and loss-of-function study on cell migration and invasion abilities were carried out by transfection of
miR-490-3p mimics or inhibitors respectively. The molecular targets of miR-490-3p were computationally identified
and experimentally verified by dual-luciferase reporter assay and western blot. Functional rescue was also
conducted to confirm miR-490-3p inhibits CRC metastasis by targeting TGF-β signaling pathway.
Results: miR-490-3p expression was persistently downregulated during CRC malignant progression, as well as in
CRC cell lines. Artificially overexpression miR-490-3p in CRC cell lines inhibited cell migration and invasion abilities
while knockdown miR-490-3p expression caused the reverse effects. TGFβR1 and MMP2/9 were the downstream
targets of miR-490-3p in CRC. Inhibition of TGFβR1 could partially recover the tumor suppression effect of miR-490-
3p.
Conclusion: miR-490-3p is downregulated during CRC malignant progression. miR-490-3p represses CRC cell
migration and invasion abilities, partially by targeting to the TGF-β signaling pathway. Taken together, miR-490-3p is
acting as a tumor suppressor in CRC.
Keywords: miR-490-3p, Colorectal cancer, Metastasis, TGF-β signaling
Background
Colorectal cancer (CRC) is one of the most common
gastrointestinal malignance and the third leading cause
of cancer-related mortality among males and females
worldwide [1]. 90 % of early-stage CRC could be cured
by clinical surgery. However, the majority of patients are
often diagnosed at an advanced stage thus with poor
prognosis [2]. Novel therapeutic targets and diagnostic
biomarkers for CRC malignant progression are urgently
demanded.
The dysregulation of many oncogenes and tumor sup-
pressor genes has been involved in the tumorigenesis
and progression of CRC [3]. In the past decades, a num-
ber of microRNAs (miRNAs) serving as oncogenes or
tumor suppressors have been demonstrated to be pivotal
regulators during tumorigenesis and progression [4].
MiRNAs are a family of small non-coding single strand
RNAs ranging from 18 to 25 nt, suppressing gene ex-
pression at post-transcriptional level by partial comple-
mentary binding to target mRNAs thus resulting in
mRNA degradation and/or translational repression. A
broad range of biological functions, such as cell prolifer-
ation, apoptosis, migration and immune response, were
under the precise regulation of miRNAs [5, 6]. Hence,
the dysregulation of several miRNAs is very critical for
CRC [7]. Among these miRNAs, miR-490-3p has been
previously reported to be significantly lower in higher
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grade ovarian carcinoma. Overexpression of miR-490-3p
promoted cell cycle arrest and apoptosis, reduced cell
migration and invasion, perhaps by targeting CDK1, Bcl-
xL, MMP2/9, CCND1 and SMARCD1 [8]. Similar
downregulation of miR-490-3p and its growth- and
metastasis-suppressive effects on gastric [9] and lung
cancer cells [10] also has been revealed. Even its sibling
miR-490-5p, which is originated from one precursor,
acts as a tumor suppressor in bladder cancer [11]. How-
ever, opposite expression tendency and effects of miR-
490-3p was observed in hepatocellular carcinoma
(HCC). Elevated expression of miR-490-3p in HCC lead
to increased cell proliferation, migration and invasion
abilities and contributed to epithelial-mesenchymal tran-
sition (EMT) [12]. Confusing dual-faced biological func-
tions of miR-490-3p prompt us to explore its roles in
CRC.
The goal of this study was to investigate the expression
and biological functions of miR-490-3p in CRC, and to
unveil the underlying molecular mechanism of CRC me-
tastasis. We found that the expression of miR-490-3p
was significantly decreased in metastasis CRC compared
with non-metastasis samples, as well as in CRC cell
lines. Overexpression of miR-490-3p in CRC cell line
LS174T and HCT116 enhanced cell migration and inva-
sion abilities. We further identified TGFβR1 as a direct
target of miR-490-3p, which was confirmed by dual-
luciferase reporter assay and western blot. MMP2 and
MMP9 were also the downstream targets of miR-490-3p.
In general, our study provided evidences to prove that
miR-490-3p acts as a tumor suppressor in CRC malig-
nant progression through TGF-β signaling pathway.
Methods
Data source
Global miRNA expression profiles of 54 cancerous and
20 non-cancerous colonic tissues were obtained from
NCBI Gene Expression Omnibus [GEO: GSE30454]
[13]. Candidate differentially expressed miRNAs were
identified from the dataset by Student’s t-test analysis as
described below. Predicted target genes with binding
sites of miR-490-3p were obtained from the TargetScan
6.0 database [14]. TGFβR1 was included in the candidate
gene list, containing a conserved miR-490-3p binding
site. All the above databases were public and free for
use.
Clinical specimens and cell culture
8 pairs of frozen CRC specimens and matched adjacent
non-tumor tissues were histopathologically diagnosed
and recruited in the past decade. In addition, another
batch of 15 non-metastasis and 15 metastasis CRC tissue
samples were also recruited during the time. The tissues
were collected at the time of surgery and stored in
RNAlater at −80 °C until further use. For the use of the
clinical materials for research purposes, informed con-
sent was obtained from each patient, and this study was
approved by the ethics committee of the Third Affiliated
Hospital of Guangzhou Medical University.
The human CRC cell lines, including HT29, SW620,
SW480, HCT-15, LS174T, HCT116, LoVo and DLD-1,
were grown in Dulbecco Minimum Essential Medium
(DMEM) (Invitrogen, Carlsbad, CA) supplemented with
10 % fetal bovine serum (FBS) (HyClone, Logan, UT)
and 1 % penicillin/streptomycin. Cells were maintained
in a humidified atmosphere at 37 °C with 5 % CO2.
RNA extraction and quantitative real-time PCR
To measure the expression level of miR-490-3p, total
miRNA from cultured cells or surgical specimens was
extracted using the mirVana miRNA Isolation Kit
(Ambion, USA) according to the manufacturer’s instruc-
tions. cDNA was synthesized from 5 ng of total miRNA
using the TaqMan miRNA reverse transcription kit (ABI,
USA), and the expression levels of miR-490-3p were
quantified using miRNA-specific TaqMan MiRNA Assay
Kit (ABI, USA) in an ABI 7500 real-time PCR machine.
U6 small nuclear RNA was used as an endogenous
control.
To measure the mRNA levels of MMP2 and
MMP9, total RNA extracted using Trizol reagent
(Invitrogen, USA) was reversely transcribed using the
ImProm-II Reverse Transcription System (Promega,
USA). Quantitative real-time PCR was performed by
using SYBR Green PCR master mix (Roche, USA) on
an ABI 7500 real-time PCR machine. The primers selected
were as the following: MMP2 forward: 5′- AGGC
CAAGTGGTCCGTGTGA-3′, reverse: 5′-TAGGTGGTG
GAGCACCA GAG-3′; MMP9 forward: 5′- ATCCGGCA
CCTCTATGGTCCTC-3′, reverse: 5′- GCACAGTAG
TGGCCGTAGAAGG-3′; expression data were normalized
to the geometric mean of housekeeping gene β-actin to
control the variability in expression levels (forward: 5′-
TGGCACCCAGCACAATGAA-3′; reverse primer, 3′-CT
AAGTCATAGTCCGCCTAGAAGCA -5′).
Plasmids construction
The full-length sequence of TGFβR1 3′ untranslated re-
gion (3′UTR) is 4888 bp long and contains one con-
served miR-490-3p binding sites from 3933 bp to
3939 bp. The region of human TGFβR1 3′UTR, from
3780 to 4176 bp, generated by PCR amplification from
genomic DNA, were cloned into the Kpn I/Xho I sites
of the pGL3-basic luciferase reporter plasmid (Promega,
USA). The primers selected were as the following:
TGFβR1-3′UTR forward: 5′- CGGGGTACCGTTGTGC
CAACGGAATAGGG -3′; reverse: 5′- CCGCTCGAG
CTCCTCTTTACAGGCTTCTCAG -3′. Mutant inserts
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containing substitutions in the miRNA complementary
sites were generated by PCR using the primers: TGFβR1-
3′UTR-mut forward:5′- CATACTTTATAGAAATAAAA
CTGCACGATTGGAGAATGCTCTGACAAATATTAA
AC-3′ and reverse,5′- GTTTAATATTTGTCAGAG
CATTCTCCAATCGTGCAGTTTTATTTCTATAAAG
TATG -3′; PCR products were cloned into the
modified pGL3 control vector (Promega, USA)
immediately downstream of the stop codon of the
luciferase gene. Wild-type and mutant inserts
were confirmed by sequencing.
Cell transfection
The miR-490-3p mimics (miR-490-3p), inhibitors (miR-
490-3p-in) and their relative negative controls (NC), ac-
companied with TGFβR1 siRNA were purchased from
RiboBio (RiboBio Co.Ltd, Guangzhou, China). Transfec-
tion of microRNA or microRNA inhibitor or their rela-
tive controls were performed using the Lipofectamine
2000 reagent (Invitrogen, USA) according to the manu-
facturer’s instruction. The final concentration of trans-
fection was 20 nM if not specified.
Wound healing assay
Cell migration ability was measured using the scratch
assay. Briefly, cells were seeded on six-well plates with
DMEM containing 10 % FBS and grown to monolayer
confluence. The cell monolayers were scratched with a
sterile pipette tip to create straight wounds. At 0 and
24 h after wounding, respectively, migration images were
captured and documented at different time points using
an inverted Olympus IX50 microscope with 10× object-
ive lens and the Image-Pro Plus software (Media
Cybernetics).
Transwell matrix penetration assay
For migration and invasion assays, cells (2 × 104) to be
tested were plated on the top side of the polycarbonate
Transwell filter with Matrigel (BD Biosciences, San Jose,
CA) coating in the upper chamber of the BioCoatTM In-
vasion Chambers (BD, Bedford, MA, USA) and incu-
bated at 37 °C for 24 h, followed by removal of cells
inside the upper chamber with cotton swabs. Invaded
cells on the membrane bottom-surface were fixed in 1 %
paraformaldehyde, stained with 0.2 % (w/v) crystal violet
solution for 15 min, and Cells adhering to the undersur-
face of the filter were counted (Ten random 100× fields
per well) using an inverted microscope. Three independ-
ent experiments were performed and the data are pre-
sented as mean ± standard deviation (SD).
3D morphogenesis assay
24-well dishes were coated with Growth Factor Reduced
Matrigel (BD Biosciences, California, USA), and covered
with growth medium supplemented with 2 % Matrigel.
Cells were trypsinized and seeded at a density of 1 × 104.
The medium was replaced with 2 % Matrigel every 3 to
4 days and microscopic images (200x magnifications)
were captured at 2 day intervals for 2 to 3 weeks.
Dual-luciferase reporter assay
HEK-293 T cells (4 × 104) were seeded in triplicates in
24-well plates and allowed to settle for 24 h. And then
100 ng of pGL3- TGFβR1-3′UTR(wt/mut), or the
control-luciferase plasmid, plus 1 ng of pRL-TK renilla
plasmid (Promega, Madison, WI), were transfected into
the cells using Lipofectamine 2000 reagent (Invitrogen
Co., Carlsbad, CA) according to the manufacturer’s rec-
ommendation. The firefly and renilla luciferase signals
were measured 48 h after transfection using the Dual
Luciferase Reporter Assay Kit (Promega, Madison, WI)
according to the manufacturer’s protocol. Three inde-
pendent experiments were performed and the data are
presented as the mean ± SD.
Western blot
The western blot analysis was performed according to
standard methods as previously described [15], using
anti-TGFβR1 antibodies (Abcam, Cambridge, MA). The
membranes were stripped and reblotted with an anti-β-
actin monoclonal antibody (Sigma, Saint Louis, MO) as
a loading control. The relative Western blot bands dens-
ity was measured by computational software ImageJ
(which has been widely used to compare the density of
bands on an agar gel or Western blot) and normalized
with sample T1 [16].
Statistical analysis
Statistical analysis was performed using SPSS 16.0 soft-
ware (SPSS Inc., USA), and the data were presented as
means ± SD. A two-tailed t-test was used to evaluate the
statistical significance of the differences between two
groups of data in all pertinent experiments in this study.
Survival analysis was carried out with the Kaplan-Meier
method. A P-value < 0.05 was considered to be statisti-
cally significant.
Results
Decreasing miR-490-3p correlates with CRC tumorigenesis
and progression
As described before, dual-faced functional roles of miR-
490-3p have been found in various cancers, however, its
correlation with CRC remains largely unknown, which
prompt us to explore its expression and function in
CRC. After data mining of previously reported global
miRNA expression profiles of 54 cancerous and 20 non-
cancerous colonic tissues [13], we identified a miRNA,
miR-490-3p, was downregulated in majority of CRC
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samples (Fig. 1a). By quantitative real-time PCR deter-
mination, we confirmed the decreasing expression of
miR-490-3p in 8 pairs of CRC tumor and adjacent non-
tumor tissue samples (Fig. 1b), as well as in all the 8
CRC cell lines (HT29, SW620, SW480, HCT-15,
LS174T, HCT116, LoVo, DLD-1) analyzed in this study
(Fig. 1c, P < 0.05). Although wide expression discrepan-
cies had been found among these patient samples and
cell lines, individual heterogeneity and the complexity of
clinical samples (including different tumor stage, tumor
size, patient age and gender, and etc.) still do not mask
this decreasing tendency. Moreover, miR-490-3p expres-
sion was further downregulated in fifteen metastasis
CRC samples, in comparison with the expression level in
fifteen matched non-metastasis CRC samples (Fig. 2a, P
< 0.05). Following-up of these patients indicated lower
expression level of miR-490-3p was associated with poor
prognosis of survival (Fig. 2b, P < 0.05). Taken together,
miR-490-3p expression was downregulated during CRC
tumorigenesis and malignant progression. miR-490-3p
perhaps acts as a tumor suppressor in CRC, which
would be determined below.
miR-490-3p suppresses CRC cell migration and invasion
abilities
To investigate the biological functions of miR-490-3p in
CRC, LS174T and HCT116 cell lines were used for gain-
of-function and loss-of-function studies. The medium-
level of miR-490-3p expression in the two cell lines were
suitable for either overexpression or knockdown modifi-
cation of the same genetic background (Fig. 1c). After
overexpression of miR-490-3p by transfection of 20 nM
synthesized mimics, or knockdown of miR-490-3p by
transfection of 20 nM synthesized inhibitors, LS174T
and HCT116 cell migration and invasion abilities were
assessed in comparison to the cells transfected with 20
nM NC respectively.
By wound healing assay, we found that overexpression
of miR-490-3p slowed down the confluence of LS174T
and HCT116 cells (Fig. 3a), while knockdown of miR-
490-3p promoted the wounds healing reversely (Fig. 4a).
Similar effects were observed in Matrigel transwell assay.
Overexpression of miR-490-3p dramatically reduced the
number of invaded cells on the membrane bottom-
surface (Fig. 3b, P < 0.05) and knockdown of miR-490-3p
increased the number of invaded cells (Fig. 4b, P < 0.05).
All the above observations suggested miR-490-3p could
suppress CRC cell migration and invasion abilities.
In addition, in a 3D morphogenesis assay, LS174T and
HCT116 cells with increased expression of miR-490-3p
presented less outward projections and spheroid morph-
ology compared to the negative control (Fig. 3c), which
was associated with an impaired aggressive ability.
Contrary phenotype was observed in CRC cells with de-
creased expression of miR-490-3p (Fig. 4c).
miR-490-3p targets TGFβR1 in CRC cells
By using a popular miRNA targets prediction algorithm
TargetScan, TGFβR1 was predicted to be a theoretical
target of miR-490-3p (Fig. 5a), which miRNA recogni-
tion element (MRE) in 3′UTR was conserved among
mammals. Western blot results showed that overexpres-
sion of miR-490-3p in CRC cell lines decreased the pro-
tein level of TGFβR1, and knockdown expression of
miR-490-3p increased the protein level of TGFβR1 in-
versely (Fig. 5b). Dual-luciferase reporter assay indicated
that miR-490-3p suppressed TGFβR1 expression by dir-
ect binding to the MRE (Fig. 5c), while mutants in the
seed region disrupted their interaction (Fig. 5d). MMP2
and MMP9 have been previously reported to be direct
target genes of miR-490-3p in ovarian cancer [8]. Here
we found that MMP2 and MMP9 mRNA expression
was downregulated after overexpression of miR-490-3p
and upregulated after knockdown of miR-490-3p
(Fig. 5e), confirming the interactions between them.
Moreover, in eight CRC patient tissue samples, a signifi-
cant reversed correlation between miR-490-3p expres-
sion and TGFβR1 protein level had been identified
(Fig. 5f, r = −0.92, P < 0.05), which further proved the
true inhibitory relationship.
Inhibition of TGFβR1 partially recovers the tumor
suppression function of miR-490-3p
To further investigate the functional consequence of the
miR-490-3p/TGFβR1 interactions in CRC, we compared
the migration abilities of CRC cells treated with TGFβR1
siRNA, miR-490-3p inhibitors, or both of them. TGFβR1
siRNA markedly reduced the TGFβR1 protein level,
while miR-490-3p inhibitors elevated the TGFβR1 pro-
tein level. Co-transfection of TGFβR1 siRNA and miR-
490-3p inhibitors partially recovered TGFβR1 expression
when compared to the cells only transfected with siRNA
(Fig. 6a). Meanwhile, the cell migration ability was
assessed by transwell matrix penetration assay for the
same treatment. Transfection of TGFβR1 siRNA de-
creased the migrated cells and transfection of miR-490-
3p inhibitors increased the migrated cells respectively.
Co-transfection of them partially but not completely re-
duced the malignant potency caused by miR-490-3p in-
hibitors (Fig. 6b). Taken together, evidences indicated
inhibition of TGFβR1 could partially recover the tumor
suppression effect of miR-490-3p.
Discussion
Human miR-490-3p gene is located in chromosome
17 (136903167-136903294 [+], GRCh38), highly
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Fig. 2 miR-490-3p expression persistently decreased during CRC progression. a Quantitative real-time PCR analysis of miR-490-3p expression in 15
metastasis CRC samples in comparison with the expression in 15 matched non-metastasis CRC samples. b Overall survival curve indicated that
lower expression level of miR-490-3p was associated with poor prognosis of CRC
Fig. 1 Downregulation of miR-490-3p in human CRC tissues and cell lines. a Global miRNA expression profile revealed miR-490-3p was downregulated
in CRC tissues versus non-neoplastic colon. Each row of the heatmap indicated one tissue sample and each column indicated one miRNA. Labels in
the right represented for miRNA symbol or probeset. Red: high expression; Green: low expression. b Quantitative real-time PCR analysis of miR-490-3p
expression in 8 pairs of CRC tumor and adjacent non-tumor tissue samples. c Quantitative real-time PCR analysis of miR-490-3p expression in 8 CRC cell
lines. *: A two-tailed t-test P-value <0.05
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conserved among mammals, indicating a fundamental
and pivotal function role during evolution [17]. How-
ever, researches concerning miR-490-3p are still very
limited. Current knowledge emphasizes its relevance
to diseases in particular various types of cancer. As
described above, miR-490-3p is likely to be a tumor
suppressor in ovarian [8], gastric [9] and lung cancer
[10] cells but acts as an oncogenic factor in liver can-
cer on the contrary [12]. Such dual-faced biological
functions have been discovered in many miRNAs,
such as miR-503-5p [18–20] and etc. Dysregulation of
miR-490-3p in CRC has been found in one large scale
screening yet [13], therefore, it’s worthy of further in-
vestigation to unveil its roles in CRC.
TGFβR1 protein is a membrane serine/threonine
protein kinase. It forms a heteromeric complex with
type II TGF-β receptors when bound to TGF-β,
transducing the TGF-β signal from the cell surface to
the cytoplasm. TGF-β signaling inhibits cell cycle G1/
S transition in the early stage of tumor onset but pro-
motes cell migration and invasion in advanced stage
of tumor [21]. In the present study, we found miR-
409-3p was downregulated not only during CRC
tumorigenesis but persistently decreased during CRC
Fig. 3 Overexpression of miR-490-3p suppresses CRC cell migration and invasion abilities. a Wound healing assay was used to assess the mobile ability
of CRC cells (LS174T and HCT116) transfected with miR-490-3p mimics or negative control respectively. miR-490-3p inhibited the wound closure
obviously (magnification: 100x). b Matrigel transwell assay revealed miR-490-3p significantly reduced the number of invaded CRC cells (P < 0.05). c Cell
3D morphology showed that LS174T and HCT116 CRC cells with increased expression of miR-490-3p presented less outward projections and spheroid
morphology, which was associated with an impaired aggressive ability (magnification: 200x). *: A two-tailed t-test P-value <0.05
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development. miR-490-3p inhibits cell migration and
invasion in part by direct targeting to TGFβR1 and
MMP2/9. Impaired expression of miR-490-3p during
CRC development led to increasing TGFβR1. And
then activated TGFβR1 phosphorylates SMAD2 which
dissociates from the receptor and interacts with
SMAD4. The SMAD2-SMAD4 complex is subsequently
translocated to the nucleus where it modulates the tran-
scription of the TGF-β-regulated genes [22]. Interestingly,
TGF-β signaling is also double-edged for cancer develop-
ment [21]. TGF-β signaling functions as tumor suppressor
on the early stage of tumorigenesis by causing cell cycle
arrest and inducing apoptosis. But over activated TGF-β
signals are often observed in many advanced carcinomas,
which have been correlated with increased tumor inva-
siveness and malignant progression. Regulation of
TGFβR1 by miRNAs had been reported in some other
diseases such as non-small cell lung cancer [23]. We
proved that decreased miR-490-3p in CRC cells result in-
creased protein level of TGFβR1 which enhanced CRC
migration and invasion by elevating TGF-β signals. Be-
sides directly promoting cell migration and invasion,
Fig. 4 Knockdown of miR-490-3p promotes CRC cell migration and invasion. a Wound healing assay was used to assess the mobile ability of CRC cells
(LS174T and HCT116) transfected with miR-490-3p inhibitors or negative control respectively. Knockdown of miR-490-3p expression markedly
accelerated the wound healing (magnification: 100x). b Transwell matrix penetration assay revealed knockdown of miR-490-3p expression
significantly increased the number of invaded CRC cells (P < 0.05). c Cell 3D morphology showed that LS174T and HCT116 CRC cells with
decreased expression of miR-490-3p presented more outward projections and irregular shapes, which was associated with an highly
aggressive ability (magnification: 200x). *: A two-tailed t-test P-value <0.05
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TGF-β signaling is also involved in EMT [24, 25], tumor
angiogenesis [26], and immunosuppression [27], which
are the key procedures of cancer metastasis. We supposed
that miR-490-3p might also regulate EMT, angiogenesis
and immune response in CRC progression. Limited to our
current capacity, this hypothesis would be verified next
time.
It’s known that one miRNA could target to hundreds
of genes, forming a complex regulating network [14].
Here we identified TGFβR1 as a novel miR-490-3p
Fig. 5 miR-490-3p targets TGFβR1 and MMP2/9 in CRC cells. a TGFβR1 was predicted to be a theoretical miR-490-3p target. Complete
base pairing in seed region of TGFβR1 3‘UTR was disrupted in constructed mutant plasmid to verify direct interaction. b Western blot
results showed that overexpression of miR-490-3p in CRC cell lines decreased the protein level of TGFβR1, and knockdown expression of
miR-490-3p increased the protein level of TGFβR1 inversely. c Dual-luciferase reporter assay indicated miR-490-3p bound to TGFβR1 3‘UTR
directly. d Disruption of seed region base pairing blocked the interaction between miR-490-3p and TGFβR1. e Quantitative real-time PCR
analysis suggested MMP2 and MMP9 were the downstream responses of miR-490-3p interference. f The relative miR-490-3p expression
and TGFβR1 protein level in 8 CRC tissues were quantified by real-time PCR and western blot respectively. Linear regression analysis of
them revealed a strong negative correlation. *: A two-tailed t-test P-value <0.05
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target. In addition, the inhibitory effects of miR-490-3p
on the mRNA level of MMP2/9 had been validated in
CRC cells. Degradation of the extracellular matrix is a
critical event during the malignant progression of cancer,
which requires a number of extracellular enzymes like
matrix metalloproteinase (MMP) [28]. MMPs have been
recognized as involved in cancer invasion and metasta-
sis, especially MMP2 and MMP9 [29, 30]. Elevated
MMP2 and MMP9 expression promotes the degradation
of type IV collagen, a major constituent of basement
membranes. Moreover, noticing that TGFβR1 siRNA
only partially rescued the malignant consequence caused
by miR-490-3p downregulation (Fig. 6), there is reason
to believe that additional genes beyond TGF-β signaling
pathway should be included in the miR-490-3p regulat-
ing network.
Conclusion
In conclusion, our studies demonstrate miR-490-3p is
persistently downregulated during CRC malignant pro-
gression. miR-490-3p inhibits CRC cell migration and
invasion abilities in part by targeting to TGFβR1 and
MMP2/9, therefore interfering TGF-β signaling trans-
duction. Taken together, miR-490-3p is acting as a
tumor suppressor in CRC.
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